Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan.

Background: Tolvaptan preserves kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD) at elevated risk of rapid progression. A trial (NCT02964273) evaluated tolvaptan safety and pharmacodynamics in children (5–17 years). However, progression risk was not part of study e...

Descripción completa

Detalles Bibliográficos

Publicado en:	Pediatric Nephrology Vol. 39; no. 5; pp. 1481 - 1491
Autores principales:	Mekahli, Djalila, Guay-Woodford, Lisa M., Cadnapaphornchai, Melissa A., Goldstein, Stuart L., Dandurand, Ann, Jiang, Huan, Jadhav, Pravin, Debuque, Laurie
Formato:	research tables/charts Journal Article
Publicado:	Springer Nature May2024
Acceso en línea:	Ver este registro en EBSCOhost